Literature DB >> 22921309

The role of choline in prostate cancer.

Hussain Mohamad Awwad1, Juergen Geisel, Rima Obeid.   

Abstract

Choline is an essential nutrient that is necessary for cell membrane synthesis and phospholipid metabolism and functions as an important methyl donor. Multiple roles for choline in cancer development have been suggested. Choline can affect DNA methylation and lead to a disruption of DNA repair. It can also modify cell signaling that is mediated by intermediary phospholipid metabolites, and it can support the synthesis of cell membranes and thus support cell proliferation. A higher intake or status of choline in plasma and tissues has been related to higher cancer risks. Prostate cancer shows elevated levels of choline uptake and levels of certain choline metabolites. Choline metabolites can be used as potential prognostic biomarkers for the management of prostate cancer patients. Targeting certain enzymes, which are related to choline metabolism, provides promising therapeutic opportunities for tumor growth arrest. This review summarizes the potential role of choline metabolism in cancer, especially in prostate cancer.
Copyright © 2012 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22921309     DOI: 10.1016/j.clinbiochem.2012.08.012

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  24 in total

Review 1.  Emerging applications of metabolomics in drug discovery and precision medicine.

Authors:  David S Wishart
Journal:  Nat Rev Drug Discov       Date:  2016-03-11       Impact factor: 84.694

2.  [18F]fluoromethylcholine as a chemotherapy response read-out in prostate cancer cells.

Authors:  Daniela E Oprea-Lager; Mitchell P van Kanten; Reindert J A van Moorselaar; Alfons J M van den Eertwegh; Peter M van de Ven; Irene V Bijnsdorp; Otto S Hoekstra; Albert A Geldof
Journal:  Mol Imaging Biol       Date:  2015-06       Impact factor: 3.488

Review 3.  Lipid metabolism in prostate cancer.

Authors:  Xinyu Wu; Garrett Daniels; Peng Lee; Marie E Monaco
Journal:  Am J Clin Exp Urol       Date:  2014-07-12

Review 4.  UPLC-MS for metabolomics: a giant step forward in support of pharmaceutical research.

Authors:  Ala F Nassar; Terence Wu; Samuel F Nassar; Adam V Wisnewski
Journal:  Drug Discov Today       Date:  2016-12-02       Impact factor: 7.851

5.  A novel three serum phospholipid panel differentiates normal individuals from those with prostate cancer.

Authors:  Nima Patel; Robert Vogel; Kumar Chandra-Kuntal; Wayne Glasgow; Uddhav Kelavkar
Journal:  PLoS One       Date:  2014-03-06       Impact factor: 3.240

6.  Tumor growth affects the metabonomic phenotypes of multiple mouse non-involved organs in an A549 lung cancer xenograft model.

Authors:  Shan Xu; Yuan Tian; Yili Hu; Nijia Zhang; Sheng Hu; Dandan Song; Zhengshun Wu; Yulan Wang; Yanfang Cui; Huiru Tang
Journal:  Sci Rep       Date:  2016-06-22       Impact factor: 4.379

Review 7.  Characterization of the Tumor Microenvironment and Tumor-Stroma Interaction by Non-invasive Preclinical Imaging.

Authors:  Nirilanto Ramamonjisoa; Ellen Ackerstaff
Journal:  Front Oncol       Date:  2017-01-31       Impact factor: 6.244

8.  Three-dimensional nuclear magnetic resonance spectroscopy: a complementary tool to multiparametric magnetic resonance imaging in the identification of aggressive prostate cancer at 3.0T.

Authors:  Michael Deal; Florian Bardet; Paul-Michael Walker; Mathilde Funes de la Vega; Alexandre Cochet; Luc Cormier; Imad Bentellis; Romaric Loffroy
Journal:  Quant Imaging Med Surg       Date:  2021-08

9.  Increased phosphatidylethanolamine N-methyltransferase gene expression in non-small-cell lung cancer tissue predicts shorter patient survival.

Authors:  David Zinrajh; Gerd Hörl; Günther Jürgens; Janja Marc; Miha Sok; Darko Cerne
Journal:  Oncol Lett       Date:  2014-04-04       Impact factor: 2.967

10.  Choline Kinase Alpha as an Androgen Receptor Chaperone and Prostate Cancer Therapeutic Target.

Authors:  Mohammad Asim; Charles E Massie; Folake Orafidiya; Nelma Pértega-Gomes; Anne Y Warren; Mohsen Esmaeili; Luke A Selth; Heather I Zecchini; Katarina Luko; Arham Qureshi; Ajoeb Baridi; Suraj Menon; Basetti Madhu; Carlos Escriu; Scott Lyons; Sarah L Vowler; Vincent R Zecchini; Greg Shaw; Wiebke Hessenkemper; Roslin Russell; Hisham Mohammed; Niki Stefanos; Andy G Lynch; Elena Grigorenko; Clive D'Santos; Chris Taylor; Alastair Lamb; Rouchelle Sriranjan; Jiali Yang; Rory Stark; Scott M Dehm; Paul S Rennie; Jason S Carroll; John R Griffiths; Simon Tavaré; Ian G Mills; Iain J McEwan; Aria Baniahmad; Wayne D Tilley; David E Neal
Journal:  J Natl Cancer Inst       Date:  2015-12-11       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.